Berit Olsen Krogh

USPTO Granted Patents = 10 (Patent Applications = 5)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 11)

Average Co-Inventor Count = 5.6

ph-index = 2

Forward Citations = 15(Granted Patents)

Location History:

Rødovre, DK (2012 - 2013)
Rodovre, DK (2013 - 2014)
Roedovre, DK (2014 - 2022)

Company Filing History:

Argos Therapeutics, Inc.

patents

Years Active: 2012-2022

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11279771 - Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161) (2022-03-22),

2. 10717784 - Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor (2020-07-21),

3. 10457743 - Antibodies recognizing the N-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity (2019-10-29),

4. 9896513 - Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor (2018-02-20),

5. 9574011 - Antibodies against tissue factor pathway inhibitor (2017-02-21),

6. 8658771 - Humanized antibodies against human interferon-alpha (2014-02-25),

7. 8652471 - Methods of treating coagulopathies using antibodies against tissue factor pathway inhibitor (2014-02-18),

8. 8361469 - Antibodies against tissue factor pathway inhibitor (2013-01-29),

9. 8361463 - Humanized antibodies against human interferon-alpha (2013-01-29),

10. 8163885 - Humanized antibodies against human interferon-alpha (2012-04-24),

Title: Berit Olsen Krogh: Innovator in Antibody Development

Introduction

Berit Olsen Krogh is a notable inventor based in Roedovre, Denmark. He has made significant contributions to the field of biomedicine, particularly in the development of innovative antibodies. With a total of 10 patents to his name, Krogh's work has the potential to impact therapeutic approaches for coagulopathy.

Latest Patents

Krogh's latest patents include groundbreaking research on antibodies capable of binding two epitopes on tissue factor pathway inhibitor (TFPI). One of his applications discloses bispecific TFPI antibodies that can specifically and simultaneously bind two epitopes within TFPI (1-161). These bispecific antibodies enhance thrombin generation by neutralizing TFPI, even in cases where TFPI concentration is elevated. Another patent reveals a combination of two monospecific TFPI antibodies, where one binds to TFPI (1-181) and the other to TFPI (182-276). Both the combination and the bispecific antibody significantly enhance thrombin generation by neutralizing full-length TFPI, even when TFPI levels are abnormally high.

Career Highlights

Throughout his career, Krogh has worked with prominent companies in the biotechnology sector, including Novo Nordisk A/S and Argos Therapeutics, Inc. His experience in these organizations has allowed him to refine his expertise in antibody development and therapeutic applications.

Collaborations

Krogh has collaborated with talented individuals in his field, including Ida Hilden and Jens Breinholt. These partnerships have contributed to the advancement of his research and the successful development of innovative solutions in biomedicine.

Conclusion

Berit Olsen Krogh is a distinguished inventor whose work in antibody development is paving the way for new treatments in coagulopathy. His innovative patents and collaborations highlight his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.